Don’t miss the latest developments in business and finance.

Zydus Cadila receives final approval for Cholestyramine for Oral Suspension USP

Image
Capital Market
Last Updated : Jul 03 2018 | 12:31 PM IST
Zydus Cadila has received final approval to market Cholestyramine for Oral Suspension USP (Questran), 4 g resin per pouch or scoopful. It is used alongwith a proper diet to lower cholesterol in the blood. Lowering cholesterol helps decrease the risk for strokes and heart attacks. It will be manufactured at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Jul 03 2018 | 12:11 PM IST

Next Story